Primary study · included by 1 review

Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study.

Wang 2024 · Wang Jianping, Zhang Jian, Gao Jie, et al. · Advances in clinical and experimental medicine : official organ Wroclaw Medical University · 2024

Included by

The Efficacy and Safety of Neoadjuvant Immunotherapy in Pan-Squamous Cell Carcinomas: A Meta-Analysis of Esophageal, Head and Neck, Cervical, Lung, Cutaneous, and Oral Squamous Cell Carcinomas.

Non-Cochrane · intervention · 2026 · cited as Wang 2024 · Supplementary Table S1; reference list

The review does not say which of its outcomes this study informs.

1 including review in total.